Doximity (DOCS) Revenue & Revenue Breakdown
Doximity Revenue Highlights
Latest Revenue (Y)
$570.40M
Latest Revenue (Q)
$138.29M
Main Segment (Y)
Subscription
Main Geography (Y)
Subscription
Doximity Revenue by Period
Doximity Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $570.40M | 19.98% |
| 2024-03-31 | $475.42M | 13.45% |
| 2023-03-31 | $419.05M | 21.98% |
| 2022-03-31 | $343.55M | 66.05% |
| 2021-03-31 | $206.90M | 77.76% |
| 2020-03-31 | $116.39M | 35.82% |
| 2019-03-31 | $85.69M | - |
Doximity generated $570.40M in revenue during NA 2025, up 19.98% compared to the previous quarter, and up 490.08% compared to the same period a year ago.
Doximity Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $138.29M | -17.98% |
| 2024-12-31 | $168.60M | 23.22% |
| 2024-09-30 | $136.83M | 8.02% |
| 2024-06-30 | $126.68M | 7.30% |
| 2024-03-31 | $118.06M | -12.73% |
| 2023-12-31 | $135.28M | 19.08% |
| 2023-09-30 | $113.61M | 4.74% |
| 2023-06-30 | $108.47M | -2.25% |
| 2023-03-31 | $110.97M | -3.73% |
| 2022-12-31 | $115.26M | 12.80% |
| 2022-09-30 | $102.19M | 12.74% |
| 2022-06-30 | $90.64M | -3.22% |
| 2022-03-31 | $93.65M | -4.31% |
| 2021-12-31 | $97.88M | 23.35% |
| 2021-09-30 | $79.35M | 9.19% |
| 2021-06-30 | $72.67M | 8.97% |
| 2021-03-31 | $66.69M | 13.59% |
| 2020-12-31 | $58.71M | 30.14% |
| 2020-09-30 | $45.11M | 23.98% |
| 2020-06-30 | $36.39M | 0.09% |
| 2020-03-31 | $36.35M | 12.11% |
| 2019-12-31 | $32.43M | - |
Doximity generated $138.29M in revenue during Q4 2025, up -17.98% compared to the previous quarter, and up 102.22% compared to the same period a year ago.
Doximity Revenue Breakdown
Doximity Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| Service, Other | $26.63M | $25.35M | $29.31M | $24.25M |
| Subscription | $543.77M | $450.07M | $389.74M | $319.30M |
Doximity's latest annual revenue breakdown by segment (product or service), as of Mar 25: Subscription (95.33%), and Service, Other (4.67%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subscription | $137.88M | $131.90M | $162.26M | $129.64M | $219.33M | $129.49M | $101.25M | $107.51M | $95.33M | $83.72M | $85.79M | $91.07M | $74.07M | $68.38M |
| Service, Other | $8.04M | $6.39M | $6.34M | $7.19M | $12.34M | $5.79M | $7.21M | $7.75M | $6.85M | $6.92M | $7.87M | $6.81M | $5.28M | $4.29M |
Doximity's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Subscription (94.49%), and Service, Other (5.51%).
Doximity Revenue Breakdown by Country
Annual Revenue by Country
| Country | Mar 22 |
|---|---|
| Subscription | $319.30M |
| Service, Other | $24.25M |
Doximity's latest annual revenue breakdown by geography, as of Mar 22: Subscription (92.94%), and Service, Other (7.06%).
Doximity Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| UHS | Universal Health Services | $15.83B | $4.28B |
| SOLV | Solventum | $8.25B | $2.07B |
| EHC | Encompass Health | $5.37B | $1.46B |
| BAX | Baxter | $4.51B | $2.81B |
| COO | Cooper Companies | $3.90B | $1.06B |
| NBIX | Neurocrine Biosciences | $2.36B | $687.50M |
| HQY | HealthEquity | $1.20B | $325.83M |
| DOCS | Doximity | $570.40M | $138.29M |
| TEM | Tempus AI | $531.82M | $255.74M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |